DUBLIN–(BUSINESS WIRE)–The “Prenatal Screening Tests – Medical Devices Pipeline Product Landscape, 2021” report has been added to ResearchAndMarkets.com’s offering.
The report provides comprehensive information about the Prenatal Screening Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Prenatal Screening Tests includes the sub-segments Free Beta Human Chorionic Gonadotropin (hCG) Tests, Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests, Alpha-Fetoprotein (AFP) Tests and Inhibin A Tests.
Scope
- Extensive coverage of the Prenatal Screening Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of Prenatal Screening Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of Prenatal Screening Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Prenatal Screening Overview
3 Products under Development
3.1 Prenatal Screening Tests – Pipeline Products by Stage of Development
3.2 Prenatal Screening Tests – Pipeline Products by Segment
3.3 Prenatal Screening Tests – Pipeline Products by Territory
3.4 Prenatal Screening Tests – Pipeline Products by Regulatory Path
3.5 Prenatal Screening Tests – Pipeline Products by Estimated Approval Date
4 Prenatal Screening Tests – Pipeline Products under Development by Companies
4.1 Prenatal Screening Companies – Pipeline Products by Stage of Development
4.2 Prenatal Screening Tests – Pipeline Products by Stage of Development
5 Prenatal Screening Companies and Product Overview
5.1 Agena Bioscience Inc Company Overview
5.2 Amity University Company Overview
5.3 Arcedi Biotech Aps Company Overview
5.4 Asuragen Inc Company Overview
5.5 BCML GmbH Company Overview
5.6 BioCeps (Inactive) Company Overview
5.7 Biocept Inc Company Overview
5.8 Biofidelity Ltd Company Overview
5.9 BioFluidica Microtechnologies LLC Company Overview
5.10 BioNano Genomics Inc Company Overview
5.11 BioReference Laboratories Inc Company Overview
5.12 Cardiff Oncology Inc Company Overview
5.13 Cellscape Corp (Inactive) Company Overview
5.14 Celula Inc Company Overview
5.15 ChromaCode Inc Company Overview
5.16 Columbia University Company Overview
5.17 Cradle Genomics Inc Company Overview
5.18 Echelon Diagnostics Inc Company Overview
5.19 ET Healthcare Inc Company Overview
5.20 Fluidigm Corp Company Overview
5.21 Fluxion Biosciences Inc Company Overview
5.22 German Cancer Research Center Company Overview
5.23 Helicos BioSciences Corporation Company Overview
5.24 iGene Laboratory Pte Ltd Company Overview
5.25 Illumina Inc Company Overview
5.26 INEX Innovate Pte Ltd Company Overview
5.27 Intignus Biotech Pvt Ltd Company Overview
5.28 Johns Hopkins University Company Overview
5.29 Juno Diagnostics Inc Company Overview
5.30 KellBenx Inc (Inactive) Company Overview
5.31 Luna Genetics Inc Company Overview
5.32 Maastricht University Medical Center Company Overview
5.33 Natera Inc Company Overview
5.34 NX Prenatal Inc. Company Overview
5.35 Oshun Medical Company Overview
5.36 Oxford Gene Technology Ltd Company Overview
5.37 Paramedical Srl Company Overview
5.38 PerkinElmer Inc Company Overview
5.39 Roche Diagnostics International Ltd Company Overview
5.40 Sequenom Inc Company Overview
5.41 Sera Prognostics Inc Company Overview
5.42 Sheba Medical Center Company Overview
5.43 Shenzhen Mindray Bio-Medical Electronics Co Ltd Company Overview
5.44 Siemens Healthcare Diagnostics Inc Company Overview
5.45 Siemens Healthineers AG Company Overview
5.46 StellarGene Technologies Pvt Ltd Company Overview
5.47 Stilla Technologies SAS Company Overview
5.48 Suzhou Basecare Medical Co Ltd Company Overview
5.49 The Chinese University of Hong Kong Company Overview
5.50 thromboDx BV Company Overview
5.51 Tufts Medical Center Company Overview
5.52 University of Cambridge Company Overview
5.53 University of Oxford Company Overview
6 Prenatal Screening- Recent Developments
6.1 Oct 21, 2021: Healius Announces Results of Annual General Meeting 2021
6.2 Sep 01, 2021: BioMerieux announce First-Half 2021 Results
6.3 Mar 11, 2021: Illumina and Harvard Pilgrim Health Care real-world evidence study demonstrates cost-effectiveness of offering NIPT to all pregnant women
7 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/snkcoh
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900